{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:30:18Z","timestamp":1780579818275,"version":"3.54.1"},"reference-count":42,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"unspecified","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["CDT-142654"],"award-info":[{"award-number":["CDT-142654"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Paul B. Helliwell Foundation Hematology Research Innovation Fund","award":["5790-7020-0708"],"award-info":[{"award-number":["5790-7020-0708"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,11,29]]},"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Individuals with sickle cell disease (SCD) and central venous catheters (CVC) are at high risk for venous thromboembolism (VTE). Minimal data exist regarding the use of anticoagulation as thromboprophylaxis of VTE in this demographic, and as a result, clinical equipoise exists. Prophylactic dose rivaroxaban, a direct oral anticoagulant, is efficacious and safe as thromboprophylaxis in other demographics, and may be an optimal agent in SCD with CVC. Prior to conducting a full clinical trial to assess rivaroxaban as thromboprophylaxis in SCD with CVC, a pilot study is needed to gauge its feasibility.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and analysis<\/jats:title>\n                  <jats:p>THromboprophylaxis In Sickle Cell Disease pilot trial is an investigator-initiated, multicentre, double-blinded, randomised controlled trial (RCT) assessing if it is feasible and safe to conduct an adequately powered RCT comparing rivaroxaban to matching placebo as thromboprophylaxis in those with SCD and CVC. Fifty adult patients with SCD and CVC will be randomised to receive either rivaroxaban 10\u2009mg daily or matching placebo for the duration of the CVC in situ for up to 1 year. After randomisation, follow-up visits will occur every 3\u2009months. The primary outcomes pertain to the feasibility of a full trial and include numbers of eligible and recruited participants. Exploratory outcomes include overall incidence of VTE and bleeding complications, as well as quality of life. If the full trial is feasible, blinding will be maintained and patients in the pilot study will be included in the full trial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Ethics and dissemination<\/jats:title>\n                  <jats:p>The trial was initially approved by the University Health Network Research Ethics Board (REB) in Toronto, Canada. All sites will obtain approval from their respective REB prior to commencement of study activities. Study results will be disseminated through presentations at medical conferences and peer-reviewed publications.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05033314\">NCT05033314<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2023-079363","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:19:34Z","timestamp":1704845974000},"page":"e079363","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["THromboprophylaxis In Sickle Cell Disease with central venous catheters (THIS): an internal pilot randomised controlled trial protocol"],"prefix":"10.1136","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct05033314","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05033314","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01036802","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3648-2406","authenticated-orcid":false,"given":"Jameel","family":"Abdulrehman","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Fort\u00e9","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, Montreal, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Tomlinson","sequence":"additional","affiliation":[{"name":"Institute for Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad","family":"Solh","sequence":"additional","affiliation":[{"name":"Division of Transfusion Medicine, Department of Pathology and Laboratory Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada"},{"name":"Division of Hematology, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Bolster","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haowei (Linda)","family":"Sun","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Bartolucci","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Assistance Publique Hopitaux de Paris, Creteil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin H M","family":"Kuo","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,1,3]]},"reference":[{"key":"2025101813360511000_14.1.e079363.1","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-013-0895-y"},{"key":"2025101813360511000_14.1.e079363.2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10047"},{"key":"2025101813360511000_14.1.e079363.3","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12744"},{"key":"2025101813360511000_14.1.e079363.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0800374"},{"key":"2025101813360511000_14.1.e079363.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814630"},{"key":"2025101813360511000_14.1.e079363.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1700518"},{"key":"2025101813360511000_14.1.e079363.7","unstructured":"Canadian Haemoglobinopathy Association consensus statement on the care of patients with sickle cell disease in Canada version 2 0. Ottawa. 2015."},{"key":"2025101813360511000_14.1.e079363.8","unstructured":"National Heart, L., and Blood Institute . Evidence-based management of sickle cell disease. Expert Panel Report 2014 2014."},{"key":"2025101813360511000_14.1.e079363.9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/bjh.14346","article-title":"Guidelines on red cell transfusion in sickle cell disease. part I: principles and laboratory aspects","volume":"176","author":"Davis","year":"2017","journal-title":"Br J Haematol"},{"key":"2025101813360511000_14.1.e079363.10","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025101813360511000_14.1.e079363.11","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11051193","article-title":"Thromboprophylaxis reduced venous thromboembolism in sickle cell patients with central venous access devices: A retrospective cohort study","volume":"11","author":"Fort\u00e9","year":"2022","journal-title":"J Clin Med"},{"key":"2025101813360511000_14.1.e079363.12","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1182\/bloodadvances.2019000940","article-title":"Bleeding in patients with sickle cell disease: a population-based study","volume":"4","author":"Hariharan","year":"2020","journal-title":"Blood Adv"},{"key":"2025101813360511000_14.1.e079363.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007903"},{"key":"2025101813360511000_14.1.e079363.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.06.011"},{"key":"2025101813360511000_14.1.e079363.15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-590323"},{"key":"2025101813360511000_14.1.e079363.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61445-7"},{"key":"2025101813360511000_14.1.e079363.17","article-title":"Anticoagulation for people with cancer and central venous catheters","volume":"6","author":"Kahale","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2025101813360511000_14.1.e079363.18","unstructured":"XARELTO product monograph Canada, Available: https:\/\/www.bayer.ca\/omr\/online\/xarelto-pm-en.pdf"},{"key":"2025101813360511000_14.1.e079363.19","unstructured":"PRADAXA product monograph Canada. 2019. Available: https:\/\/www.boehringer-ingelheim.ca\/sites\/ca\/files\/documents\/pradaxapmen.pdf"},{"key":"2025101813360511000_14.1.e079363.20","unstructured":"ELIQUIS product monograph Canada. 2019. Available: https:\/\/www.pfizer.ca\/sites\/g\/files\/g10050796\/f\/201903\/ELIQUIS_PM_E_222811_12-Mar-2019_Marketed.pdf"},{"key":"2025101813360511000_14.1.e079363.21","unstructured":"LIXIANA product monograph Canada. 2019. Available: https:\/\/www.servier.ca\/sites\/default\/files\/webform\/products\/PM_Lixiana_%2026%20JUL%202017%20EN.pdf?ts=1535161192"},{"key":"2025101813360511000_14.1.e079363.22","unstructured":"WARFARIN product monograph Canada. 2019. Available: https:\/\/www.bms.com\/assets\/bms\/ca\/documents\/productmonograph\/COUMADIN_EN_PM.pdf"},{"key":"2025101813360511000_14.1.e079363.23","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13140"},{"key":"2025101813360511000_14.1.e079363.24","doi-asserted-by":"crossref","DOI":"10.1186\/1477-7525-2-22","article-title":"A new instrument for measuring anticoagulation-related quality of life: development and preliminary validation","volume":"2","author":"Samsa","year":"2004","journal-title":"Health Qual Life Outcomes"},{"key":"2025101813360511000_14.1.e079363.25","unstructured":"Institute, N.C . Common Terminology Criteria For Adverse Events (CTCAE), Available: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm"},{"key":"2025101813360511000_14.1.e079363.26","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/jth.13626","article-title":"Reproducibility of clinical events Adjudications in a trial of venous thromboembolism prevention","volume":"15","author":"Girard","year":"2017","journal-title":"J Thromb Haemost"},{"key":"2025101813360511000_14.1.e079363.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0906598"},{"key":"2025101813360511000_14.1.e079363.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1113572"},{"key":"2025101813360511000_14.1.e079363.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1302507"},{"key":"2025101813360511000_14.1.e079363.30","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/00043426-199511000-00011","article-title":"Long-term central venous access in patients with sickle cell disease. incidence of thrombotic and infectious complications","volume":"17","author":"Abdul-Rauf","year":"1995","journal-title":"J Pediatr Hematol Oncol"},{"key":"2025101813360511000_14.1.e079363.31","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/ajh.2830290303","article-title":"Totally Implantable intravenous catheters in the management of sickle cell anemia","volume":"29","author":"Phillips","year":"1988","journal-title":"Am J Hematol"},{"key":"2025101813360511000_14.1.e079363.32","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22230"},{"key":"2025101813360511000_14.1.e079363.33","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-119716","article-title":"Is there a role for Thromboprophylaxis in sickle cell patients with central venous access Devies","volume":"132","author":"Fort\u00e9","year":"2018","journal-title":"Blood"},{"key":"2025101813360511000_14.1.e079363.34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199406093302303"},{"key":"2025101813360511000_14.1.e079363.35","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23683"},{"key":"2025101813360511000_14.1.e079363.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199807023390102"},{"key":"2025101813360511000_14.1.e079363.37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050460"},{"key":"2025101813360511000_14.1.e079363.38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-392340"},{"key":"2025101813360511000_14.1.e079363.39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1411133"},{"key":"2025101813360511000_14.1.e079363.40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611770"},{"key":"2025101813360511000_14.1.e079363.41","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.861625"},{"key":"2025101813360511000_14.1.e079363.42","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-10-1","article-title":"A Tutorial on pilot studies: the what, why and how","volume":"10","author":"Thabane","year":"2010","journal-title":"BMC Med Res Methodol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-079363","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T20:36:19Z","timestamp":1760819779000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-079363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,3]]},"published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1136\/bmjopen-2023-079363"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-079363","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]}}}